[go: up one dir, main page]

WO2004072265A3 - Procedes pour controler in vivo des activites de medicaments - Google Patents

Procedes pour controler in vivo des activites de medicaments Download PDF

Info

Publication number
WO2004072265A3
WO2004072265A3 PCT/US2004/004118 US2004004118W WO2004072265A3 WO 2004072265 A3 WO2004072265 A3 WO 2004072265A3 US 2004004118 W US2004004118 W US 2004004118W WO 2004072265 A3 WO2004072265 A3 WO 2004072265A3
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
methods
genes
activities
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/004118
Other languages
English (en)
Other versions
WO2004072265A2 (fr
Inventor
Michael Burczynski
Natalie Twine
Andrew J Dorner
William L Trepicchio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to AU2004210986A priority Critical patent/AU2004210986A1/en
Priority to EP04710266A priority patent/EP1592811A2/fr
Priority to CA002515677A priority patent/CA2515677A1/fr
Publication of WO2004072265A2 publication Critical patent/WO2004072265A2/fr
Publication of WO2004072265A3 publication Critical patent/WO2004072265A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés, des systèmes et un équipement utilisés pour contrôler in vivo des activités de CCI-779 ou d'autres médicaments. Cette invention permet d'identifier de nombreux gènes d'activité de médicament. Les profils d'expression de ces gènes dans des cellules mononucléaires du sang périphérique peuvent être modulés par CCI-779 ou par d'autres médicaments. Ces gènes peuvent ainsi être utilisés en tant que marqueurs de substitution pour contrôler in vivo des activités de médicaments.
PCT/US2004/004118 2003-02-11 2004-02-11 Procedes pour controler in vivo des activites de medicaments Ceased WO2004072265A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2004210986A AU2004210986A1 (en) 2003-02-11 2004-02-11 Methods for monitoring drug activities in vivo
EP04710266A EP1592811A2 (fr) 2003-02-11 2004-02-11 Procedes pour controler in vivo des activites de medicaments
CA002515677A CA2515677A1 (fr) 2003-02-11 2004-02-11 Procedes pour controler in vivo des activites de medicaments

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44613303P 2003-02-11 2003-02-11
US60/446,133 2003-02-11
US45978203P 2003-04-03 2003-04-03
US60/459,782 2003-04-03
US53824604P 2004-01-23 2004-01-23
US60/538,246 2004-01-23

Publications (2)

Publication Number Publication Date
WO2004072265A2 WO2004072265A2 (fr) 2004-08-26
WO2004072265A3 true WO2004072265A3 (fr) 2005-03-03

Family

ID=32872756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004118 Ceased WO2004072265A2 (fr) 2003-02-11 2004-02-11 Procedes pour controler in vivo des activites de medicaments

Country Status (4)

Country Link
EP (1) EP1592811A2 (fr)
AU (1) AU2004210986A1 (fr)
CA (1) CA2515677A1 (fr)
WO (1) WO2004072265A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569299B2 (en) 2010-06-08 2013-10-29 Merck Sharp & Dohme Corp Prolylcarboxypeptidase inhibitors
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US8921394B2 (en) 2010-04-27 2014-12-30 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006006948A2 (fr) * 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
EP1588142A4 (fr) 2002-11-21 2007-10-31 Wyeth Corp Methodes de diagnostic de rcc et autres tumeurs solides
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
US20060194211A1 (en) * 2003-04-29 2006-08-31 Burczynski Michael E Methods for prognosis and treatment of solid tumors
WO2006066133A2 (fr) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2006097388A2 (fr) * 2005-02-08 2006-09-21 Innogenetics N.V. Variants d'acides nucleiques dans le gene c1qr1 associe a une immunite innee modifiee
WO2006122319A2 (fr) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP1762575A1 (fr) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
AU2007359085A1 (en) * 2006-11-16 2009-03-26 Gentron, Llc Methods, systems, and compositions for cancer diagnosis
ES2599986T3 (es) * 2009-08-11 2017-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2571855B1 (fr) 2010-05-17 2014-12-24 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de prolylcarboxypeptidase
EP3710032A4 (fr) * 2017-11-15 2021-12-15 The Translational Genomics Research Institute Tests de biomarqueurs de substitution et procédés de tests de chimie sanguine standard
CN112852964B (zh) * 2021-03-08 2022-02-11 镇江市第一人民医院 一种环状RNA hsa_circ_0059707及其特异性扩增引物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (fr) * 1999-01-06 2000-07-13 Genenews Inc. Technique de detection de transcrits geniques dans le sang et leur utilisation
WO2001081916A2 (fr) * 2000-04-24 2001-11-01 Beth Israel Deaconess Medical Center, Inc. Procedes permettant l'evaluation du rejet apres une transplantation
WO2002040000A2 (fr) * 2000-11-15 2002-05-23 Wyeth Utilisation du cci-779 en tant qu'agent antineoplasique
WO2004048933A2 (fr) * 2002-11-21 2004-06-10 Wyeth Methodes de diagnostic de rcc et autres tumeurs solides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356114A2 (fr) * 2001-01-31 2003-10-29 Whitehead Institute For Biomedical Research Diagnostic de tumeur cerebrale et prediction de resultat de traitement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040749A2 (fr) * 1999-01-06 2000-07-13 Genenews Inc. Technique de detection de transcrits geniques dans le sang et leur utilisation
WO2001081916A2 (fr) * 2000-04-24 2001-11-01 Beth Israel Deaconess Medical Center, Inc. Procedes permettant l'evaluation du rejet apres une transplantation
WO2002040000A2 (fr) * 2000-11-15 2002-05-23 Wyeth Utilisation du cci-779 en tant qu'agent antineoplasique
WO2004048933A2 (fr) * 2002-11-21 2004-06-10 Wyeth Methodes de diagnostic de rcc et autres tumeurs solides

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Product Catalogue", January 2002, AFFYMETRIX, XP002295173 *
BURCZYNSKI ET AL.: "Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S51, XP002295167, ISSN: 0959-8049 *
DATABASE SOURCE 2 September 2004 (2004-09-02) *
DIPAOLA R S ET AL: "Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. JUL 1999, vol. 17, no. 7, July 1999 (1999-07-01), pages 2213 - 2218, XP002295169, ISSN: 0732-183X *
ELIT LAURIE: "CCI-779 Wyeth.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) AUG 2002, vol. 3, no. 8, August 2002 (2002-08-01), pages 1249 - 1253, XP008037562, ISSN: 1472-4472 *
PERALBA JOSEP MARIA ET AL: "Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 AUG 2003, vol. 9, no. 8, 1 August 2003 (2003-08-01), pages 2887 - 2892, XP002295172, ISSN: 1078-0432 *
PERALBA JOSEP-MARIA ET AL: "Pharmacodynamic evaluation of the rapamycin ester CCI-779", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 1000 - 1001, XP001182924, ISSN: 0197-016X *
RININGER J A ET AL: "Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity", DRUG DISCOVERY TODAY 01 DEC 2000 UNITED KINGDOM, vol. 5, no. 12, 1 December 2000 (2000-12-01), pages 560 - 568, XP002295171, ISSN: 1359-6446 *
SCHULZE-KOOPS H ET AL: "Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1).", CLINICAL AND EXPERIMENTAL IMMUNOLOGY. NOV 1996, vol. 106, no. 2, November 1996 (1996-11-01), pages 190 - 196, XP002295168, ISSN: 0009-9104 *
See also references of EP1592811A2 *
SU A I ET AL: "Molecular classification of human carcinomas by use of gene expression signatures", CANCER RESEARCH 15 OCT 2001 UNITED STATES, vol. 61, no. 20, 15 October 2001 (2001-10-15), pages 7388 - 7393, XP002295170, ISSN: 0008-5472 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US8921394B2 (en) 2010-04-27 2014-12-30 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US8569299B2 (en) 2010-06-08 2013-10-29 Merck Sharp & Dohme Corp Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors

Also Published As

Publication number Publication date
EP1592811A2 (fr) 2005-11-09
WO2004072265A2 (fr) 2004-08-26
CA2515677A1 (fr) 2004-08-26
AU2004210986A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
WO2004072265A3 (fr) Procedes pour controler in vivo des activites de medicaments
WO2006078287A3 (fr) Inhibiteurs de pde4b
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
WO2007047781A3 (fr) Gels hydrophobes reticules pour revetements bioabsorbables de vecteur de medicament
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
WO2009092087A3 (fr) Différenciation, identification et modulation sélectives de cellules th17 humaines
WO2008091835A3 (fr) Endoprothèses médicales implantables
WO2008036658A3 (fr) Procédé et système d'infusion contrôlée de substances thérapeutiques
WO2003074662A3 (fr) Enzymes scd utilisees comme modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2008070346A3 (fr) Procédés permettant de traiter la douleur avec moins de nausées et de vomissement
WO2005016227A3 (fr) Methodes et compositions pharmaceutiques servant a moduler l'activation d'heparanase et leurs utilisations
WO2005082341A3 (fr) Agents non peptidyl a activite de type phsp20 et utilisations correspondantes
WO2010019914A3 (fr) Agents anti-arythmie, procédés pour leur utilisation, procédés pour leur identification et kits pertinents
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
WO2004094673A8 (fr) Methodes de surveillance d'activites de medicaments in vivo
IL172416A0 (en) Modified human acid sphingomyelinase having increased activity, and methods for making the same
WO2007002087A3 (fr) Cdc6s servant de modificateurs de la voie pten/akt et procedes pour les utiliser
WO2005010148A3 (fr) Marks de modification de la voie pten et methodes d'utilisation
WO2004087876A3 (fr) Utilisation de globules rouges pour faciliter l'activation cellulaire
WO2005003297A3 (fr) Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes
WO2004024882A3 (fr) Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes
WO2005052132A3 (fr) Utilisation de modulateurs de la morphogenese de ramification comme genes modificateurs de la morphogenese de ramification et leurs procedes d'utilisation
WO2006099183A3 (fr) Nek8 utilises en tant que modificateurs de la voie pten/akt et procedes d'utilisation associes
WO2006036613A3 (fr) Genes mrac utilises en tant que modificateurs de la voie rac et procedes d'utilisation correspondants
WO2005072470A3 (fr) Genes mbm en tant que modificateurs de la morphogenese de ramification et methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004710266

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2515677

Country of ref document: CA

Ref document number: 541700

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004210986

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004210986

Country of ref document: AU

Date of ref document: 20040211

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004210986

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004710266

Country of ref document: EP